CME: Improving the Management of Severe Asthma in Patients with Type 2 Inflammation
- Published on Sunday, 03 March 2019 14:04
- Written by Juan Carlos Ivancevich
0.50 AMA PRA Category 1 Credit(s)™ 0.50 AANP Contact Hours 0.50 AAPA Category 1 Credit(s)
Primary care physicians, NPs, PAs, and other clinicians who care for patients with asthma.
Nicola A. Hanania, MD, MS
Associate Professor of Medicine
Pulmonary and Critical Care Medicine
Director, Airways Clinical Research Center
Baylor College of Medicine
Reynold A. Panettieri, Jr., MD
Vice Chancellor, Translational Medicine and Science
Director, Rutgers Institute for Translational Medicine and Science
Professor of Medicine, Robert Wood Johnson Medical School
Emeritus Professor of Medicine, University of Pennsylvania
Rutgers Institute for Translational Medicine and Science
New Brunswick, NJ
|1.||Describe the role of Type 2 inflammation in asthma pathophysiology and the phenotypic and endotypic characterization of asthma with Type 2 inflammation.||2.||Review the mechanism of action, efficacy, and safety of targeted agents approved for the management of severe, uncontrolled asthma with Type 2 inflammation and those in late-stage development.|
|3.||Incorporate agents targeted at Type 2 inflammation into the management of appropriate patients with severe, uncontrolled asthma not responding to ICS and bronchodilator therapy.|
CONTINUING EDUCATION CREDIT
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Purdue University College of Pharmacy and MCM Education. Purdue University is accredited by the ACCME to provide continuing medical education for physicians.
Purdue University designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit.™ Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity is approved for 0.5 contact hour(s) of continuing education (which includes 0.25 hours of pharmacology) by the American Association of Nurse Practitioners. Activity ID 19023554. This activity was planned in accordance with AANP Accreditation Standards and Policies.
This activity has been reviewed by the AAPA Review Panel and is compliant with AAPA CME Criteria. This activity is designated for 0.50 AAPA Category 1 CME credits. Approval is valid for one year from 02/28/2019. PAs should only claim credit commensurate with the extent of their participation.